FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Nepoliting Ferson		on <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Galante Josej	<u>)11 C</u>		INC [ CPIX ]	X	Director	10% Owner			
(Last) (First) (Middle) 2525 WEST END AVENUE		(Middle)	Date of Earliest Transaction (Month/Day/Year)		Officer (give title below)	Other (specify below)			
	DAVENUE		04/13/2020						
SUITE 950			4. If Amendment, Date of Original Filed (Month/Day/Year)	6 Indiv	idual or Joint/Group Filing	(Check Applicable			
(Street)			in in , and individually a distribution of the control of the cont	Line)	idda: or come croup : ming	, (Circon / ppiloabio			
NASHVILLE	TN	37203		X	Form filed by One Repo	rting Person			
,—————————————————————————————————————	114				Form filed by More than Person	One Reporting			
(City)	(State)	(Zip)							
1									

(Street) NASHVILLE TN	37203					X	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City) (State)	(Zip)							1 013011			
	Table I - Non-Derivative S	Securities Acq	uired,	Dis	posed of,	or Ben	eficially	/ Owned			
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	04/13/2020		P		75 <sup>(1)</sup>	A	\$4.03	17,767	D		
Common Stock	04/15/2020		P		150 <sup>(1)</sup>	A	\$4.05	17,917	D		
Common Stock	04/17/2020		P		150 <sup>(1)</sup>	A	\$4.04	18,067	D		
Common Stock	04/21/2020		P		150 <sup>(1)</sup>	A	\$4.03	18,217	D		
Common Stock	04/23/2020		P		150 <sup>(1)</sup>	A	\$4.03	18,367	D		
Common Stock	04/27/2020		P		150(1)	Α	\$4.02	18,517	D		
Common Stock	04/29/2020		P		150 <sup>(1)</sup>	A	\$4.01	18,667	D		
Common Stock	05/01/2020		P		150 <sup>(1)</sup>	A	\$4.01	18,817	D		
Common Stock	05/05/2020		P		150 <sup>(1)</sup>	A	\$3.99	18,967	D		
Common Stock	05/07/2020		P		150 <sup>(1)</sup>	A	\$3.97	19,117	D		
Common Stock	05/11/2020		P		150 <sup>(1)</sup>	A	\$4.02	19,267	D		
Common Stock	05/13/2020		P		150 <sup>(1)</sup>	A	\$3.93	19,417	D		
Common Stock	05/14/2020		P		75 <sup>(1)</sup>	A	\$3.81	19,492	D		
Common Stock	05/15/2020		P		75 <sup>(1)</sup>	A	\$3.76	19,567	D		
Common Stock	05/18/2020		P		75 <sup>(1)</sup>	Α	\$3.82	19,642	D		
Common Stock	05/19/2020		P		75 <sup>(1)</sup>	A	\$3.78	19,717	D		
Common Stock	05/20/2020		P		75 <sup>(1)</sup>	A	\$3.77	19,792	D		
Common Stock	05/21/2020		P		75 <sup>(1)</sup>	A	\$3.68	19,867	D		
Common Stock	05/22/2020		P		75 <sup>(1)</sup>	A	\$3.61	19,942	D		
Common Stock	05/26/2020		P		75 <sup>(1)</sup>	A	\$3.59	20,017	D		
Common Stock	05/27/2020		P		75 <sup>(1)</sup>	A	\$3.49	20,092	D		
Common Stock	05/28/2020		P		<b>75</b> <sup>(1)</sup>	A	\$3.34	20,167	D		
Common Stock	05/29/2020		P		75 <sup>(1)</sup>	A	\$3.35	20,242	D		
Common Stock	06/01/2020		P		75 <sup>(1)</sup>	A	\$3.45	20,317	D		
Common Stock	06/02/2020		P		<b>75</b> <sup>(1)</sup>	A	\$3.35	20,392	D		
Common Stock	06/03/2020		P		75 <sup>(1)</sup>	Α	\$3.29	20,467	D		
Common Stock	06/04/2020		P		75 <sup>(1)</sup>	Α	\$3.31	20,542	D		
Common Stock	06/05/2020		P		75 <sup>(1)</sup>	A	\$3.44	20,617	D		
Common Stock	06/08/2020		P		75 <sup>(1)</sup>	A	\$3.54	20,692	D		
Common Stock	06/09/2020		P		75 <sup>(1)</sup>	A	\$3.48	20,767	D		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

## **Explanation of Responses:**

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.

## Remarks:

Joseph C. Galante by /s/
Michael Bonner as attorney- 06/12/2020

in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.